IsoPlexis Launches IsoLight Single-Cell Early Adopter Program

IsoPlexis has installed its ground-breaking IsoLight benchtop system at Fred Hutchinson Cancer Research Center, as part of the company’s Early Adopter Program. The sample-to-answer IsoLight benchtop system analyzes IsoPlexis’ IsoCode chip to provide clinical and translational researchers a powerful, yet straightforward solution for establishing immune response functional correlates with outcome in key therapeutic areas like CAR-T and other cellular immunotherapies. The IsoCode Chip was recognized as The Scientist’s and Fierce Life Science’s #1 innovation of 2017 for its ability to provide both single-cell sensitivity and highly multiplexed and quantitative functional ELISA detection together for the first time. The data from the IsoCode Chip demonstrates improved capacity in predicting CAR-T patient responses pre-infusion compared to existing technologies. The integration of precision imaging and fluidics with user-friendly software makes it an easy-to-use instrument yielding highly dimensional, single-cell proteomic data.

Share This Article
Be in the Know.
Unlock Resources

We will always keep your personal information safe. Complete this form to get unlimited access to all of our web resources and join over 10,000 leading researchers who receive industry pioneers' backed data straight to their inbox. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy.

You may unsubscribe and update your email subscription at any time.